Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Clinical pharmacology of high-dose cisplatin

  • 56 Accesses

  • 68 Citations


Although nephrotoxicity has frequently limited conventional treatment with cisplatin to doses of 100–120 mg/m2 per cycle, vigorous chloruresis can permit the administration of high-dose cisplatin (200 mg/m2 per cycle) with minimal nephrotoxicity. Systemic toxicities are worsened, but therapeutic response seems to be enhanced. The pharmacokinetics of cisplatin in plasma and urine were examined to assess the causes of these effects. Plasma disappearance of ultrafiltrable platinum was well-described by a single exponential for each patient. The mean t1/2 was 50% longer for patients receiving high-dose cisplatin than for patients receiving conventional doses. The total systemic exposure was three times greater in the high-dose group, which tends to explain the systemic toxicity and improved tumor efficacy, but not the lack of nephrotoxicity. It is suggested that the kidneys of patients in the high-dose group were relatively protected by dilution of active Pt species in the urine in the tubule lumen as well as by high chloride ion concentrations in the urine.

This is a preview of subscription content, log in to check access.


  1. 1.

    Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, Repta AJ (1979) Pharmacokinetics of non-protein-bound platinum species following administration ofcis-dichlorodiammineplatinum (II). Cancer Treat Rep 63:1515–1521

  2. 2.

    Chary KK, Higby DJ, Henderson ES, Swinerton KD (1977) Phase I study of high-dosecis-dichlorodiammineplatinum (II) with forced diuresis. Cancer Treat Rep 61:367–370

  3. 3.

    Einhorn LH, Donahue J (1977)cis-Diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293–298

  4. 4.

    Gormley PE, Bull JM, LeRoy AF, Cysyk R (1979) Kinetics ofcis-dichlorodiammineplatinum. Clin Pharmacol Ther 25:351–357

  5. 5.

    Greene RF, Chatterji DC, Hiranaka PK, Galleli JF (1979) Stability of cisplatin in aqueous solution. Am J Hosp Pharm 36:38–43

  6. 6.

    Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ (1981) Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29:658–664

  7. 7.

    Hrushesky WJM, Borch R, Levi F (1982) Circadian time dependence of cisplatin urinary kinetics. Clin Pharmacol Ther 32:330–339

  8. 8.

    Jacobs C, Kalman SM, Tretton M, Weiner MW (1980) Renal handling ofcis-diamminedichloroplatinum (II). Cancer Treat Rep 64:1223–1226

  9. 9.

    LeRoy AF, Wehling ML, Sponseller AL, Friauf WS, Solomon SE, Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184–191

  10. 10.

    Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65:307–314

  11. 11.

    Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100:19–24

  12. 12.

    Schmoll H-J, Weiss J, Arnold H, Dolken G, Mayr T, Hoffman L, Douwes FW, Hossfeld DK (1983) Platinum ultra high dose/etoposide/bleomycin in testicular carcinoma: toxicity and activity. (Abstract) J Invest New Drugs 2:124

  13. 13.

    Weiner MW, Jacobs C (1983) Mechanism of cisplatin nephrotoxicity. Fed Proc 42:2974–2978

  14. 14.

    Wittes RE, Cvitkovic E, Shah J, Gerold FP, Strong EW (1977)cis-Dichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 61:359–366

  15. 15.

    Young RC, Von Hoff DD, Gormley P, Makuch R, Cassidy J, Howser D, Bull JM (1979)cis-Diamminedichloroplatinum (II) for the treatment of advanced ovarian cancer. Cancer Treat Rep 63:1539–1544

Download references

Author information

Correspondence to Jerry M. Collins.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Corden, B.J., Fine, R.L., Ozols, R.F. et al. Clinical pharmacology of high-dose cisplatin. Cancer Chemother. Pharmacol. 14, 38–41 (1985). https://doi.org/10.1007/BF00552723

Download citation


  • Platinum
  • Clinical Pharmacology
  • Conventional Treatment
  • Therapeutic Response
  • Systemic Exposure